From TIME magazine:
Research suggests that the psychedelic drug MDMA, an empathogenic stimulant also known as Molly or ecstasy, can spark changes in the brain that induce a childlike state of neuroplasticity and help forge new neural connections.
(It could well be approved for PTSD by the U.S. Food and Drugs Administration in August after two advanced stage trials showed significant benefits.)
Researchers are also studying other psychedelics as well, like the powerful drug ibogaine.
Read more
MDMA therapy for PTSD could become a new treatment option for millions of people living with trauma. The clinical evidence is growing.
Read more
Here’s the official statement from MAPS!
The results confirmed findings from MAPP1; no serious adverse events were observed among the participants
In a first for psychedelic-assisted therapy trials, more than half of MAPP2 participants identify as people of color
Read more
Veterans are turning to psychedelic treatments for PTSD healing.
Read more
Great news! The first Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder (PTSD) replicated and expanded on Phase 2 results indicating MDMA-assisted therapy may be an effective and cost-saving treatment for PTSD resulting from any cause.
Read more
A ‘magic mushroom’ nasal spray has been designed to make microdosing easier for people trying to treat PTSD or depression. An Oregon company has developed a magic mushroom nasal spray in Jamaica – where psilocybin is legal – for controlled, metered-dosing known as ‘microdosing’.
Read more
As a first responder, Nick Watchorn had seen many terrible things in the course of his career. But the massive shooting of April 28, 1986 in Tanzania, Australia, completely shook his handle on reality. Now Nick is part of the experimental studies on therapeutic MDMA or PTSD treatment.
Read more
The following interview with Wyly Gray documents his own story of suicidal ideation to personal transformation, and why he shifted the focus of his veteran advocacy group Veterans of War after finding great healing with ayahuasca.
Read more
The largest psychedelic research center in the world, and the first of its kind in the United States, will open at Johns Hopkins Medicine in Maryland. Funded by $17 million from private donors, the Center for Psychedelic and Consciousness Research will conduct research into the use of psychedelic drugs in the treatment of addiction, PTSD, depression, Alzheimer's disease and more.
Read more
More research with promising results on how pharmaceutical-grade MDMA can be used in combination with psychotherapy, to help patients who have a severe form of PTSD that has not responded to other treatments.
Read more